Because innovation fuels our pipeline
As we think about the future of medicine, we’re exploring new frontiers across a diverse and robust range of product candidates and disease states. All with the vision of developing game-changing solutions for patients.
| Candidate | Target | Isotope | Indication/Disease Area | Pre-clinical | Phase I | Phase II | Phase III | Reg. Filing | |
|---|---|---|---|---|---|---|---|---|---|
| Prostate Cancer |
|
PSMA | 177Lu | Metastatic Prostate Cancer | |||||
|
PNT2002 is a small molecule PSMA-targeted 177Lu-based radiotherapeutic for metastatic castration-resistant prostate cancer (SPLASH study – NCT04647526). |
|||||||||
|
GRPR | 68Ga | Metastatic Prostate Cancer | ||||||
|
LNTH-2401 is a novel radiodiagnostic targeting the gastrin-releasing peptide receptor. |
|||||||||
|
GRPR | 177Lu | Metastatic Prostate Cancer | ||||||
|
LNTH-2402 is a novel gastrin-releasing peptide receptor targeted radiotherapeutic for solid tumors including prostate, breast, lung and other cancers. |
|||||||||
| Neuroendocrine Tumors |
|
SSTR2 | 177Lu | GEP-NETs | |||||
|
PNT2003 is a somatostatin receptor targeted radiotherapeutic, in development for gastroenteropancreatic neuroendocrine tumors. |
|||||||||
|
SSTR2 | 68Ga | GEP-NETs | ||||||
|
LNTH-2501/EVG-001 is an investigational kit for the preparation of Gallium-68 DOTATOC which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adults and children. |
|||||||||
| Other Solid Tumors |
|
FAP | 64Cu | Tumor / Fibrosis assessment | |||||
|
LNTH-1363S is a fibroblast activation protein, copper-64 labeled radiodiagnostic with broad potential imaging applicability and use in oncology. |
|||||||||
|
LRRC15 | Undisc. | Solid Tumors | ||||||
|
LNTH-2403 is a Leucine-Rich Repeat-Containing Protein 15 targeted radiotherapeutic. It received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for the treatment of osteosarcoma. |
|||||||||
|
TROP2 | Undisc. | Solid Tumors | ||||||
|
LNTH-2404 is a Trophoblast cell surface antigen-2 targeted radiotherapeutic. |
|||||||||
|
CCK2R | 177Lu/68Ga | Small Cell Lung Cancer | ||||||
|
LNTH-2503/EVG-321 is a highly specific peptide vector, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
|||||||||
|
Undisc. | 177Lu/68Ga | Glioblastoma | ||||||
|
LNTH-2505/EVG-311 is a molecularly targeted tracer that binds to a glial cell surface molecule which may be used for the diagnosis and treatment of glioblastoma (GBM) and potentially other glial tumors. |
|||||||||
|
Undisc. | 177Lu/68Ga | Pancreatic Ductal Adenocarcinoma | ||||||
|
LNTH-2507/EVG-332 is a radiotracer targeting a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). |
|||||||||
|
Undisc. | 177Lu/68Ga | Lobular Breast Cancer | ||||||
|
LNTH-2509/EVG-341 is a radiotracer targeting a cell surface molecule for the treatment of lobular breast cancer. |
|||||||||
| Neurology / Other |
|
Tau | 18F | Alzheimer’s Disease | |||||
|
Florquinitau is a next-generation tau-targeting radiodiagnostic for Alzheimer’s disease. |
|||||||||
|
ß amyloid | 18F | Alzheimer’s Disease | ||||||
Each of these product candidates is an investigational drug that has not yet been approved as safe and effective.
PSMA, Prostate specific membrane antigen; GRPR, Gastrin-releasing peptide receptor; SSTR2, Somatostatin receptor 2; GEP-NETs, Gastroenteropancreatic neuroendocrine tumors; FAP, Fibroblast activation protein; LRRC15, Leucine-Rich Repeat-Containing Protein 15; TROP2, Trophoblast cell surface antigen-2; CCK2R, cholecystokinin-2 receptor.
1. Collaboration with POINT Biopharma Global Inc. 2. Also known as 68Ga-RM2 3. Also known as 177Lu-RM2
*We are actively partnering with researchers on these assets to provide appropriate biomarkers in relevant studies. If interested, please contact biomarkers@lantheus.com for more information.
Clinical Trials
Lantheus is committed to Find, Fight and Follow® disease for patients. As part of that commitment, we ensure that Diversity, Equity and Inclusion (DEI) is a top priority when it comes to clinical trials. Because we believe everyone should have access to the latest trials and treatments.
For more information about clinical trials involving products being developed by Lantheus, please contact our clinical team at clinicaltrials@lantheus.com.
Information on all clinical trials involving products being developed by Lantheus is offered by the National Institutes of Health here.
Digital and Pharmaceutical Services
Our innovation includes the very latest technologies in digital and pharmaceutical services. We’re pioneering AI software platforms that use deep learning algorithms to help clinicians and researchers perform quantitative assessments in cancer imaging. This focus on data-driven solutions helps us partner with healthcare professionals to empower more informed diagnostic and treatment decisions that can lead to improved patient outcomes.
Expanded Access Program
Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease.
Lantheus is focused on conducting clinical trials required by regulatory authorities to thoroughly answer important scientific questions about the potential risks and benefits of our investigational products. A clinical trial is a research program conducted to comprehensively evaluate the safety and effectiveness of an investigational product to treat or diagnose a disease or condition. An investigational product is a product that has not been reviewed or approved by the regulatory authority responsible for determining safety and effectiveness in a particular country. In the United States, the regulatory authority is the Food and Drug Administration or FDA. The data from clinical trials is provided to a regulatory authority, such as the FDA, to obtain regulatory approval for the investigational product. After receiving regulatory approval, Lantheus can make the product commercially available and healthcare providers (HCPs) can prescribe the product for patients who are most likely to benefit from the product.